News

Under this licence, Mesoblast will now make MPC products commercially available to doctors and hospitals across Australia for a patient’s own, or autologous, use in the repair and

The vaccine has been developed to prevent or delay the recurrence sarcoma at Memorial Sloan-Kettering Cancer Center (MSKCC) where preclinical and early clinical development completed in 2009. MabVax

GSK stated that the post-marketing study is designed to examine the comparative cardiovascular safety of Rosiglitazone (Avandia) and Pioglitazone (Actos) in patients with type 2 diabetes which was

Gilead Sciences has posted a net income of $712.1m for the second quarter 2010, or $0.79 per diluted share, compared to $571.4m, or $0.61 per diluted share, for

SiDMAP and Roche have presented the results of the study, entitled ‘A Novel Approach for the Treatment of Type 2 Diabetes (T2D): Characterisation of a Potent, Orally Active,

Tibotec said that TMC278 is an investigational product, and the safety and efficacy has not yet been established. Echo (TMC278-TiDP6-C209) and Thrive (TMC278-TiDP6-C215) are pivotal Phase 3, double-blind,

Amylin Pharma has posted a net loss, excluding a restructuring charge of $3.4m. Non-GAAP operating loss was $7.4m, a 67% improvement compared to $22.4m for the same period

The agreement funds research at the Gladstone Center for Translational Research led by Gladstone investigator Katerina Akassoglou, PhD and establishes the new Lundbeck Center for Neurovascular and Immuno-imaging

John O’Keefe, CEO of ITelagen, said: “Medficiency has strong established relationships with providers throughout the Mid-Atlantic and Northeast corridor and is a trusted source for their physician clients.